STOCK TITAN
  1. Home
  2. News
  3. CDNA

Caredx Inc - CDNA STOCK NEWS

Welcome to our dedicated news page for Caredx (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Caredx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Caredx's position in the market.

News
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
CareDx, a precision medicine company, granted an option to purchase 700,706 shares of common stock and 487,804 restricted stock units to its new President and CEO, John Hanna. The option has an exercise price of $8.20 and will vest over four years, while the RSUs will vest in four equal, annual installments beginning on April 15, 2025. This grant was approved by the board of directors as an inducement material to Mr. Hanna's employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
none
-
News
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
Rhea-AI Summary
CareDx, Inc. appoints John W. Hanna as the new President and CEO, bringing over two decades of executive leadership experience in the molecular diagnostics and life sciences tools industries. Hanna aims to drive sustainable growth and innovation at CareDx, focusing on improving patient outcomes and expanding the company's product portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.48%
Tags
management
-
News
CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) announces presentation of latest data at ISHLT 44th Annual Meeting showcasing benefits of surveillance with HeartCare. The company will highlight developments in its cardiothoracic portfolio, including AlloSure Heart, AlloMap Heart, HeartCare, AlloSure Lung, and AiCAV. Leading experts will discuss the use of these technologies in heart and lung transplantation, emphasizing the clinical utility of surveillance testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.41%
Tags
none
News
CareDx Appoints Bryan Riggsbee to Its Board of Directors
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) welcomes Bryan Riggsbee to its Board of Directors, bringing financial expertise and experience from Myriad Genetics and LabCorp. Riggsbee's background in revenue cycle management and molecular diagnostics will enhance CareDx's strategic growth and business development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
management
-
News
CareDx Announces Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
CareDx, Inc. (CDNA) reported total revenue of $280.3 million for 2023, surpassing updated guidance. The company achieved growth in Testing Services for the second consecutive quarter, with $209.7 million in revenue. Despite challenges, they ended the year with $235.4 million in cash and securities, repurchased shares, and received Medicare coverage for key products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.47%
Tags
earnings
-
News
CareDx to Participate in the Raymond James & Associates’ 45th Annual Institutional Investors Conference
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) to participate in Raymond James & Associates’ 45th Annual Institutional Investors Conference. The company will present on March 6, 2024, focusing on precision medicine for transplant patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
conferences
News
CareDx to Report Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
CareDx, Inc. (CDNA) will report financial results for Q4 and full year 2023 on February 28, 2024. The company focuses on healthcare solutions for transplant patients and caregivers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
conferences earnings
-
News
CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) announces its participation in the 2024 Tandem Meetings to showcase its digital solutions and advancements in cellular therapy and transplant monitoring. The company will present data on AlloHeme and AlloCell at the event, highlighting their potential in treatment response monitoring and relapse detection post-transplant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
-
News
CareDx Issues Statement in Patent Infringement Case
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) has been found to have not infringed on Natera, Inc.'s patent 10,655,180 but was found to have infringed on patent 11,111,544. The District of Delaware jury awarded Natera damages of $83,679,521 in lost profits and $12,535,500 in past royalties for alleged infringement by AlloSure from September 2021 through August 2023. CareDx intends to seek judicial review of the verdict. The decision does not impact patient or physician access to CareDx's current offerings, including AlloSure or AlloMap.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) is sponsoring the Annual American Society of Transplant Surgeons (ASTS) Winter Symposium to highlight new real-world use cases using its testing and digital solutions for improved patient risk management. The company is focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. Leading transplant experts will demonstrate how CareDx's molecular testing services, digital solutions, and risk assessment tools can improve access and outcomes within transplantation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
clinical trial
Stock CDNA logo
Caredx Inc

Nasdaq:CDNA

CDNA Rankings

#3176 Ranked by Market Cap
#5231 Ranked by Stock Gains
N/A Ranked by Dividends

CDNA Stock Data

441.67M
50.37M
3.75%
100.35%
10%
Medical Laboratories
Health Care and Social Assistance
Link
US
South San Francisco

About CDNA

caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos